OOIR: Observatory of International Research

Papers

(The H4-Index of Dermatologic Therapy is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
	93
Issue Information	84
Exploring and expanding frontiers in dermatology: Indigenous African dermatology	77
Cryptococcal meningitis associated with interleukin‐17 inhibitor use for psoriasis	62
Macrophage Migration Inhibitory Factor and Gene Polymorphism (rs755622G>C) in Unstable Vitiligo Patients	50
Ultraviolet A Combined with Narrow‐Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow‐Band Ultraviolet B	47
Tofacitinib for the Treatment of Refractory Progressive Vitiligo: A Retrospective Case Series	46
Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis	45
Microneedle fractional radiofrequency for atrophic acne scars: In vivo evaluation of results by 3D analysis and reflectance confocal microscopy	43
Topical Timolol for ingrown nail post‐avulsion refractory wound	42
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis	42
Two birds with one stone: Successful treatment with methotrexate in a patient with generalized eruptive keratoacanthoma of Grzybowski and rheumatoid arthritis	41
Comparison of Green‐Synthesized Silver Nanoparticle Shampoo Created by Moringa and Bergamot Extraction Versus 2% Ketoconazole Shampoo for Scalp Seborrheic Dermatitis: A Prospective, Randomized, Double	39
Tofacitinib in resistant chronic actinic dermatitis: A case series	39
The case of granuloma annulare associated with SARS‐CoV ‐2 infection	38
Seroconversion after anti‐SARS‐CoV ‐2 mRNA vaccinations among moderate‐to‐severe psoriatic patients receiving systemic biologicals	37
Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the “minimal disease activity” parameter	36
Epidemiology, clinical presentation, and management of pemphigoid nodularis: An update from Iran	35
Ulcerative injection site reaction after third COVID ‐19 vaccine dose with mRNA ‐1273	35
New‐onset systemic lupus erythematosus after ChAdOX1 nCoV‐19 and alopecia areata after BNT162b2 vaccination against SARS‐CoV‐2	33
Fat herniation over striae distansea in focal dermal hypoplasia treated with 2940 nm Er: YAG Laser	32
Case report: Pyogenic granuloma—just salt, a simple and pain‐free treatment	32
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al.	32
Cutaneous lupus erythematosus variants responsive to J anus kinase inhibition	32
Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication	30

Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients	30
Real‐World Guselkumab Response and Drug Survival in Australian Patients With Psoriasis: Results From the Australasian Psoriasis Registry	30
	29
Efficacy and Safety of Incobotulinumtoxin‐A for Nonfacial Aesthetic Indications: A Prospective Case Series on Calf Contouring	29
Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib	29
	29